<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) is a multisystem immune-mediated <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorder</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The choice of treatments depends on organ involvements and its severity </plain></SENT>
<SENT sid="2" pm="."><plain>The treatments for pediatric patients usually consist of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi>, but some of them are refractory to these treatments </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-alpha) appears to play an important role in the immunopathogenesis in BD </plain></SENT>
<SENT sid="4" pm="."><plain>We describe two patients with <z:hpo ids='HP_0011463'>childhood-onset</z:hpo> BD, successfully treated by anti-TNF agents </plain></SENT>
<SENT sid="5" pm="."><plain>One patient, a 18-year-old male, was diagnosed as having BD at 8 years of age </plain></SENT>
<SENT sid="6" pm="."><plain>He developed <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> and <z:hpo ids='HP_0002573'>bloody diarrhea</z:hpo> at 17 years of age </plain></SENT>
<SENT sid="7" pm="."><plain>Gastrointestinal endoscopic examination revealed esophageal and ileocolic ulceration consistent with intestinal BD </plain></SENT>
<SENT sid="8" pm="."><plain>Methylpredonisolone pulse therapy and <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> were administrated, but did not respond </plain></SENT>
<SENT sid="9" pm="."><plain>Infliximab infusions (4 mg/kg) were given at weeks of 0, 2, 6, and then every 8 weeks </plain></SENT>
<SENT sid="10" pm="."><plain>A dramatic improvement in gastrointestinal symptoms and extraintestinal manifestations were observed </plain></SENT>
<SENT sid="11" pm="."><plain>Another patient, a 9-year-old girl, developed recurrent <z:hpo ids='HP_0000155'>oral ulcers</z:hpo> and <z:mp ids='MP_0000376'>folliculitis</z:mp> at 4 years of age </plain></SENT>
<SENT sid="12" pm="."><plain>She was diagnosed as having BD at 6 years of age, and treated with <z:chebi fb="0" ids="23359">colchicines</z:chebi>, <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>She was suffering from <z:hpo ids='HP_0001945'>fever</z:hpo>, malaise, and <z:hpo ids='HP_0002829'>arthralgia</z:hpo> in addition to mucocutaneous manifestation </plain></SENT>
<SENT sid="14" pm="."><plain>At 8 years of age, etanercept was started at a dosage of 25 mg subcutaneously twice a week </plain></SENT>
<SENT sid="15" pm="."><plain>A resolution of the systemic and mucocutaneous symptoms was achieved </plain></SENT>
<SENT sid="16" pm="."><plain>Furthermore, she was free from <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> in three months </plain></SENT>
<SENT sid="17" pm="."><plain>Anti-TNF therapy would be a good choice for juvenile BD refractory to conventional treatments </plain></SENT>
</text></document>